Filing Analysis
Definitive Healthcare Corp. has filed an 8-K to furnish its financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Report date: August 10, 2026
- Reporting period: Second Quarter ended June 30, 2026
- The filing includes Exhibit 99.1 containing the earnings press release
- Signed by Casey Heller, Chief Financial Officer
Definitive Healthcare Corp. received a notice from Nasdaq stating it is in violation of the minimum bid price requirement ($1.00) after failing to maintain that price for 30 consecutive business days between May 6, 2026, and June 17, 2026.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to meet minimum bid price requirement ($1.00)
- Potential for a reverse stock split to regain compliance
- Risk of delisting if compliance is not met within the 180-day window or subsequent extension.
📋 Key Facts
- Nasdaq notified the company on June 18, 2026, regarding a violation of Nasdaq Listing Rule 5450(a)(1).
- The deficiency is due to the closing bid price being below $1.00 for 30 consecutive business days.
- The company has a 180-day compliance period ending on December 15, 2026, to regain compliance.
- To regain compliance, the stock must close at or above $1.00 for at least ten consecutive business days.
- The company explicitly mentioned considering a reverse stock split as a potential remedial action.
Definitive Healthcare Corp. reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. Shareholders approved the election of Class II directors, the ratification of Deloitte & Touche LLP as auditors, and an increase in the 2021 Equity Incentive Plan share pool.
📋 Key Facts
- Election of Chris Egan, Sastry Chilukuri, and Samuel A. Hamood as Class II directors for three-year terms expiring in 2029.
- Ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026.
- Approval to increase the 2021 Equity Incentive Plan share pool by 15,000,000 shares, raising the total from 30,972,789 to 45,972,789.
- Approval of executive compensation on a non-binding, advisory basis.
- Record date for voting was April 13, 2026, with 105,456,979 Class A and 38,225,333 Class B shares outstanding.
Definitive Healthcare Corp. announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as Exhibit 99.1.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The press release was issued and the 8-K was filed on May 7, 2026.
- The report was signed by Casey Heller, Chief Financial Officer.
- The information was furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Definitive Healthcare Corp. terminated its Nominating Agreement with Spectrum (SE VII DHC AIV, L.P.) following the resignation of Spectrum's board designee. The agreement previously granted Spectrum the right to nominate a director as long as it maintained at least a 5% ownership stake.
🚩 Red Flags
- The termination of the agreement and the resignation of the designee suggest that a major institutional shareholder (Spectrum) may have reduced its ownership stake below the 5% threshold or is exiting its position.
📋 Key Facts
- The Nominating Agreement was originally dated September 17, 2021.
- Spectrum's board designee, Jeff Haywood, resigned from the board of directors on March 30, 2026.
- The Company and Spectrum entered into a termination agreement on April 3, 2026, permanently ending the Nominating Agreement.
- The right to nominate a director was contingent on Spectrum and its affiliates beneficially owning at least 5% of the total shares outstanding.
Jeff Haywood resigned from the Board of Directors and the Human Capital Management and Compensation Committee of Definitive Healthcare Corp. effective March 30, 2026. The resignation was not due to any disagreements, and the board size was subsequently reduced from nine to eight members.
📋 Key Facts
- Jeff Haywood resigned from the Board of Directors and the Human Capital Management and Compensation Committee on March 30, 2026.
- The resignation was effective immediately.
- The company stated there were no disagreements regarding operations, policies, or practices.
- The Board size was reduced from 9 to 8 members.
- The Compensation Committee size was reduced from 3 to 2 members.
Definitive Healthcare Corp. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2025
- Filing date: February 26, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- The press release is included as Exhibit 99.1
Definitive Healthcare Corp. filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2025. The filing primarily serves as a vehicle to provide the press release containing these results via Exhibit 99.1.
📋 Key Facts
- The company reported financial results for the third quarter ended September 30, 2025.
- The announcement was made on November 6, 2025.
- Financial results were furnished via a press release (Exhibit 99.1) rather than filed under Section 18 liabilities.
Definitive Healthcare Corp. filed an 8-K to furnish its second quarter 2025 financial results (ended June 30, 2025) via a press release.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Financial results were furnished via Exhibit 99.1
Definitive Healthcare Corp. announced the resignation of Jill Larsen from its Board of Directors and her role as Chair of the Compensation Committee, effective July 21, 2025. The company also appointed Scott Stephenson to replace her on the Compensation Committee.
📋 Key Facts
- Jill Larsen resigned from the Board and the Human Capital Management and Compensation Committee effective July 21, 2025.
- Resignation attributed to increased responsibilities at her current employer; no disagreements with company operations reported.
- Board size reduced from 10 members to 9 members.
- Scott Stephenson appointed as a new Board member and Chair of the Compensation Committee.
Definitive Healthcare Corp. announced the elimination of the Chief Operating Officer position as part of an organizational redesign. The current COO, Kate Shamsuddin Jensen, will depart the company on August 1, 2025.
🚩 Red Flags
- Elimination of a C-suite position (COO) often signals internal restructuring or cost-cutting measures.
- Departure of an executive 'without cause' can sometimes indicate friction in leadership transitions, though it is common in reorganizations.
📋 Key Facts
- Kate Shamsuddin Jensen's role as Chief Operating Officer is being eliminated due to organizational design changes.
- The departure date is set for August 1, 2025.
- The termination is classified as 'without cause' for purposes of employment and equity compensation agreements.
- Effective date of the event reported: June 25, 2025.
Definitive Healthcare Corp. held its 2025 Annual Meeting of Stockholders on June 5, 2025. The meeting resulted in the election of three Class I directors, ratification of Deloitte & Touche LLP as independent auditors for fiscal year 2025, and advisory approval of executive compensation.
📋 Key Facts
- Annual Meeting held on June 5, 2025.
- Three nominees (Kevin Coop, Jason Krantz, Lauren Young) elected to Class I directors for terms expiring in 2028.
- Deloitte & Touche LLP ratified as independent auditor for fiscal year ending December 31, 2025.
- Stockholders approved executive compensation on a non-binding advisory basis.
Definitive Healthcare Corp. filed an 8-K to furnish its financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: First Quarter ended March 31, 2025
- The company furnished financial results through Exhibit 99.1 (Press Release)
- Signed by Richard Booth, Chief Financial Officer
Definitive Healthcare Corp. announced a leadership transition in its finance department, appointing Casey Heller as the new CFO effective June 2, 2025, following the departure of current CFO Richard Booth on June 1, 2025.
🚩 Red Flags
- Succession timing: The outgoing CFO departs one day before the incoming CFO starts (June 1 vs June 2), creating a potential single-day leadership gap.
📋 Key Facts
- Richard Booth will depart as CFO effective June 1, 2025.
- Casey Heller appointed as new CFO effective June 2, 2025.
- Heller's base salary is set at $375,000 with a 60% target bonus opportunity.
- Promotion includes an initial RSU grant with a target value of $1,500,000 vesting over two years.
- Annual equity awards include RSUs (target $1,462,500) and PSUs (target $787,500).
- The company also issued its Q4 and FY 2024 financial results via press release on February 27, 2025.
Definitive Healthcare Corp. entered into an amendment to its credit agreement on January 16, 2025, establishing a $175 million term loan and a $50 million revolving credit facility. The proceeds were used to repay existing indebtedness and cover related fees.
🚩 Red Flags
- Debt is secured by a lien on substantially all company assets (fixed assets and intangibles).
- Interest rate step-ups are tied to the Total Net Leverage Ratio, creating potential cost increases if leverage rises.
📋 Key Facts
- Entered into DHH Credit Agreement Amendment on January 16, 2025.
- Established a $175 million Term Facility and a $50 million Revolving Credit Facility.
- Facilities mature on January 16, 2030.
- Term loan requires quarterly principal amortization of 5.0% starting after the initial full fiscal quarter.
- Interest rates are based on ABR or Term SOFR plus a margin (1.00%-1.50% for ABR; 2.00%-2.50% for SOFR).
- Interest rates and unused commitment fees include step-up provisions of 0.25% based on the Total Net Leverage Ratio.
- Collateral includes a lien on substantially all assets of DHH, its subsidiaries, and AIDH Buyer, LLC.
Definitive Healthcare Corp. announced the departure of CFO Richard Booth effective June 1, 2025, following discussions regarding his role scope. Additionally, the company authorized a $100 million stock repurchase program and entered into a voting agreement with Advent International.
🚩 Red Flags
- Departure of CFO following 'discussions regarding the scope of the role' can sometimes indicate internal friction or strategic shifts.
- The departure is not immediate, creating a long transition period (6 months) which may cause uncertainty during the search for a successor.
📋 Key Facts
- CFO Richard Booth to depart effective June 1, 2025 (or upon successor appointment).
- Departure is classified as termination without 'cause'.
- Board awarded Mr. Booth 92,379 time-vesting RSUs to ensure smooth transition, vesting Nov 1, 2025.
- Board authorized a new $100 million Class A Common Stock repurchase program expiring Dec 31, 2025.
- Entered into a voting agreement with Advent International regarding shares exceeding 40.3% of outstanding Voting Securities.
Definitive Healthcare Corp. announced the promotion of Kate Shamsuddin Jensen from Chief Strategy Officer to Chief Operating Officer, effective October 1, 2024. The move includes a revised compensation package consisting of a $360,000 base salary and a new RSU grant.
📋 Key Facts
- Kate Shamsuddin Jensen promoted to COO effective October 1, 2024.
- New annual base salary: $360,000.
- Target performance-based cash bonus: 60% of base salary.
- Grant of 113,379 time-vesting RSUs valued at $500,000.
- RSU vesting schedule: Two equal installments on the first and second anniversaries of the effective date.
Definitive Healthcare Corp. filed an 8-K to furnish its second quarter 2024 financial results (ended June 30, 2024) via a press release.
📋 Key Facts
- Report date: August 5, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Financial results were furnished via press release in Exhibit 99.1
Definitive Healthcare Corp. reported preliminary Q2 2024 results featuring a massive $363.6 million goodwill impairment and revised its full-year 2024 guidance. Additionally, the company announced the resignation of its Chief Revenue Officer, effective August 2, 2024.
🚩 Red Flags
- Significant non-cash goodwill impairment ($363.6M) drastically impacting net loss.
- Executive departure (CRO) occurring simultaneously with significant financial volatility.
- Extreme variance in GAAP Net Loss per share: $(1.81) vs $(0.08) YoY.
- Potential for operational disruption due to the CRO's resignation.
📋 Key Facts
- Q2 2024 preliminary revenue expected at $63.7 million (up 5% YoY from $61.0 million).
- Reported a massive $363.6 million goodwill impairment charge in Q2 2024.
- Expected Q2 2024 operating loss of $(369.6) million, compared to $(12.1) million in Q2 2023.
- Revised full-year 2024 revenue guidance to a range of $247 – $251 million.
- Chief Revenue Officer Carrie Lazorchak resigned effective August 2, 2024; sales organization will report directly to CEO Kevin Coop.
Definitive Healthcare Corp. disclosed a supplemental equity grant to newly appointed CEO Kevin Coop to compensate for value shortfall caused by share price volatility.
🚩 Red Flags
- Equity compensation adjustment suggests significant stock price volatility during the transition period.
📋 Key Facts
- Kevin Coop was appointed CEO effective June 24, 2024.
- The company granted Mr. Coop 186,192 time-vesting restricted stock units (RSUs) on July 4, 2024.
- Vesting schedule: 25% on July 1, 2025, and 6.25% per quarter thereafter until fully vested over three years.
- The grant was intended to offset equity value shortfall due to share price volatility between the appointment announcement and his start date.
Definitive Healthcare Corp. announced the appointment of Kevin Coop as new CEO, effective June 24, 2024, replacing founder Jason Krantz who will transition to Executive Chairman. The filing also details results from the company's 2024 Annual Meeting of Stockholders.
🚩 Red Flags
- Significant equity incentive package ($7.5M RSU + ~1.1M PSUs) may lead to future dilution.
- High stock price hurdles in PSU grants suggest management is targeting significant upside/recovery from current levels.
📋 Key Facts
- Kevin Coop appointed CEO and Class I director, effective June 24, 2024.
- Jason Krantz steps down as Interim CEO to become Executive Chairman.
- Coop's compensation includes a $500,000 base salary and a target bonus of 100% of base salary.
- Incentive package includes an Initial RSU Grant with a target value of $7,500,000 and 1,137,038 performance-vesting RSUs (PSUs).
- PSU vesting is tied to stock price hurdles: $10.00, $15.00, $20.00, and $27.00.
- Annual Meeting results: Ratified Deloitte & Touche LLP as independent auditor for FY 2024; approved executive compensation on an advisory basis.
Definitive Healthcare Corp. filed an 8-K to furnish its financial results for the first quarter ended March 31, 2024. The filing primarily serves as a vehicle to provide the quarterly press release via Exhibit 99.1.
📋 Key Facts
- Report date: May 7, 2024
- Reporting period: First quarter ended March 31, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results
- Information furnished under Item 2.02 is not deemed 'filed' for purposes of Section 18 liability
Definitive Healthcare Corp. filed an 8-K to furnish its financial results for the fourth quarter and fiscal year ended December 31, 2023. This is a routine earnings release filing.
📋 Key Facts
- Reported date: February 28, 2024
- Covers Q4 and full fiscal year ended December 31, 2023
- The information was furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Definitive Healthcare Corp. announced the departure of CEO Robert Musslewhite, effective January 16, 2024. The company has appointed founder and Executive Chairman Jason Krantz as Interim CEO.
🚩 Red Flags
- Sudden departure of a sitting CEO (termination without cause).
- Leadership transition occurring mid-cycle/post-quarterly results.
- Multiple items in one filing (Item 2.02 and Item 5.02) indicating significant corporate movement.
📋 Key Facts
- CEO Robert Musslewhite stepped down from his role as CEO and Board member on January 16, 2024.
- The departure is characterized as a termination without 'cause'.
- Separation agreement includes 3 months of accelerated vesting for time-based equity awards (totaling 15 months).
- Company will reimburse Musslewhite up to $15,000 in legal fees.
- Founder Jason Krantz appointed as Interim CEO effective January 16, 2024.
- The company reaffirmed previously announced guidance for the quarter ended December 31, 2023.
Definitive Healthcare Corp. announced a restructuring plan on January 3, 2024, aimed at reducing operating costs and improving margins through workforce reductions. The company expects to incur significant pre-tax cash charges in the first half of 2024 as part of this initiative.
🚩 Red Flags
- Significant workforce reduction (154 employees) indicating a shift in cost structure or pressure on margins.
- Material restructuring charges ($6.5M-$7.2M cash + $1.5M non-cash) impacting near-term GAAP results.
📋 Key Facts
- The Company committed to a restructuring plan on January 3, 2024.
- Plan involves a reduction of the current workforce by 154 people.
- Estimated pre-tax cash restructuring charges: $6.5 million to $7.2 million in H1 2024.
- Estimated non-cash charge related to vesting share-based awards: approximately $1.5 million.
- The plan is expected to be substantially complete by the end of Q2 2024.